Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck Sharp & Dohme gets European approval for Isentress
The commission’s decision is applicable to the 27 member states of the European Union (EU), including France, Germany, Italy, Spain and the UK. Separate national licenses, based on
The commission’s decision is applicable to the 27 member states of the European Union (EU), including France, Germany, Italy, Spain and the UK. Separate national licenses, based on
The supplemental new drug application (sNDA) application includes 48-week data from two phase III studies, ARTEMIS (antiretroviral therapy with TMC114 examined in naive subjects) and TITAN (TMC114/ritonavir in
The Phase I trial will evaluate the safety and efficacy of CB3304 (noscapine) administered daily to patients with relapsed or refractory multiple myeloma. The trial will be conducted
The new drug application (NDA) has been submitted for two indications, treatment of adults with worsening heart failure and treatment of hyponatremia. These indications are based on data
The requested correction relates to FDA’s assessment of progression-free survival (PFS) in the Phase III trial of Genasense that was presented to the Oncology Drug Advisory Committee (ODAC)
Baobaole chewable tablets are a traditional Chinese medicine used to treat gastric and general abdomen discomfort. This drug stimulates appetites and promotes digestion with mild and lasting effects.
The company is operating profitably and the past twelve months revenues were approximately $58.5 million. ParadigmHealth, based in New Jersey, is a leading provider of innovative, consumer-centric decision
The BT Test is being made available to a select number of physicians in the Phoenix market as part of the company’s initial market release. The BT (biomarker
CardioVations’ product line includes the Port-Access products for performing minimally invasive cardiac valve procedures. The CardioVations product line is expected to generate sales of more than $20 million
The FDA has recently published a draft guidance on studies designed to show non-inferiority as a basis for approval of antibacterial drug products and has requested that Pfizer